Home > Insider Trading > Filing (0001209191-20-037087)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649094	Vaxcyte Inc.	PCVX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1551966	Lorne Robert Hopfner	C/O Vaxcyte, Inc. 353 Hatch Drive Foster City CA 94404		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-06-16	1,692,494	$0.00	1,692,494	No	4	C	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Acquisiton	2020-06-16	226,236	$0.00	1,918,730	No	4	C	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Acquisiton	2020-06-16	211,237	$0.00	2,129,967	No	4	C	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Acquisiton	2020-06-16	93,000	$16.00	2,222,967	No	4	P	Indirect	By Pivotal bioVenture Partners Fund I, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	C	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	C	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	P	Indirect	By Pivotal bioVenture Partners Fund I, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-06-16	1,692,494	$0.00	1,692,494	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-06-16	226,236	$0.00	226,236	$0.00
Common Stock	Series D Preferred Stock	Disposition	2020-06-16	211,237	$0.00	211,237	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.
The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.
The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.
The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.